Eli Lilly
-
Business
Eli Lilly’s LLY Stock Surges on Drug Tariff Boost and Trial Shifts
LLY stock rallies as Eli Lilly benefits from U.S. tariff protections, a favorable drug pricing outlook, and pipeline trial adjustments.
Read More » -
Business
Lilly Eyes 2025 Approval for Obesity Pill as Pivotal Phase 3 Trial Approaches
Eli Lilly’s orforglipron, a once-daily oral weight-loss pill, is set to enter a pivotal Phase 3 trial in non-diabetic obese…
Read More »
